-- 根據週四提交給上海證券交易所的文件顯示，人福健康（SHA:600079）旗下子公司已獲得中國監管機構批准，將進行治療急性疼痛的藥物RFUS-188的臨床試驗。 該藥物針對週邊κ阿片受體，無需穿過血腦屏障，可望消除傳統鴉片類藥物的成癮性、呼吸抑制及其他嚴重副作用。 該公司股價在近期交易中下跌1%。
Related Articles
International
Swiss Jobless Rate Inches Down to 3% in April
Switzerland's unemployment rate stood at 3% in April, down from 3.1% in the previous month, according to data from the State Secretariat for Economic Affairs published Thursday.At the end of April, 142,902 individuals were registered as unemployed, down by 3,353 from a month ago.
$^SSMI
Asia
Pansar Unit Bags MYR235 Million Water Treatment Plant Upgradation Deal
Pansar (KLSE:PANSAR) unit Perbena Emas secured a contract worth 234.9 million ringgit from Sarawak's Rural Water Supply Department (JBALB) to upgrade the Kaki Wong Water Treatment Plant, according to a Wednesday Malaysian bourse filing.Shares slid 1% in Thursday's midday trade.The project covers the construction of a new 30 MLD water treatment plant, a raw water intake system, booster pump stations, pipelines, a reservoir, and supporting buildings, including staff quarters. It also involves upgrading and refurbishing the existing plant and administrative facilities.Deal work is set to begin in June this year, with completion targeted in 30 months, it said.
$KLSE:PANSAR
International
China's May Day Holiday Consumption Up 14%
China's consumption-related industries saw sales revenue jump 14% year on year during the May Day holiday, according to the State Taxation Administration.Tourism and entertainment services rose 21%, while cultural services climbed 42% and sports services surged 44%.Health services jumped 40%, with health consultation services up 41%. Catering revenue rose 31%, driven by bars and teahouses at 52% and snack services at 42%.
$^SSEC$^SZSE